连花清瘟颗粒与阿奇霉素序贯疗法在肺炎支原体肺炎患儿中的应用研究

Study on application of Lianhua Qingwen Granules and azithromycin sequential therapy in children with Mycoplasma pneumoniae pneumonia

目的分析肺炎支原体(MP)肺炎患儿采用连花清瘟颗粒与阿奇霉素序贯疗法联合治疗的效果。方法98例MP肺炎患儿,使用随机数字表法分为研究组与对照组,各49例。对照组患儿采用阿奇霉素序贯疗法治疗,研究组在对照组基础上联合连花清瘟颗粒治疗。比较两组疗效、症状与体征恢复时间、肺功能[用力肺活量(FVC)、呼气峰流速(PEF)]、临床肺部感染量表(CPIS)评分、炎症因子[白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)]、生活质量评分、不良反应发生情况。结果研究组治疗总有效率95.92%高于对照组的81.63%,差异有统计学意义(P<0.05)。研究组退热、咳嗽缓解、啰音消失时间分别为(3.02±1.02)、(4.68±1.69)、(4.04±0.70)d,短于对照组的(4.41±1.42)、(6.02±2.02)、(5.05±0.75)d,差异有统计学意义(P<0.05)。治疗后,研究组FVC(2.30±0.24)L、PEF(192.60±17.08)L/min高于对照组的(1.85±0.23)L、(169.55±18.20)L/min,CPIS评分(1.45±0.55)分低于对照组的(1.87±0.42)分,差异有统计学意义(P<0.05)。治疗后,研究组IL-6、TNF-α、CRP分别为(30.12±5.88)pg/ml、(30.45±4.85)pg/ml、(10.75±3.82)mg/L,低于对照组的(35.24±7.08)pg/ml、(40.56±5.02)pg/ml、(14.28±3.70)mg/L,差异有统计学意义(P<0.05)。治疗后,研究组生活质量评分(88.85±5.45)分高于对照组的(82.65±6.02)分,差异有统计学意义(P<0.05)。两组不良反应发生率比较,结果无差异性(P>0.05)。结论MP肺炎患儿采用连花清瘟颗粒与阿奇霉素序贯疗法联合治疗效果确切,能够促进症状与体征恢复,改善肺功能、肺部感染情况与炎症因子水平,保障生活质量,安全性较为理想,适于临床推广。

Objective To analyze the effect of Lianhua Qingwen Granules and azithromycin sequential therapy in children with Mycoplasma pneumoniae(MP)pneumonia.Methods 98 children with MP pneumonia were divided into a study group and a control group using random number method,each with 49 cases.The control group was treated with azithromycin sequential therapy,and the study group was treated with Lianhua Qingwen Granules based on the control group.Both groups were compared in terms of efficacy,recovery time of symptoms and signs,pulmonary function[forced vital capacity(FVC),peak expiratory flow rate(PEF)],clinical pulmonary infection scale(CPIS)score,inflammatory factors[interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),C-reactive protein(CRP)],quality of life score,and occurrence of adverse reactions.Results The total effective rate of the study group was 95.92%,which was higher than 81.63%of the control group,and the difference was statistically significant(P<0.05).The time of fever reduction,cough remission and rale disappearance in the study group were(3.02±1.02),(4.68±1.69)and(4.04±0.70)d,which were shorter than(4.41±1.42),(6.02±2.02)and(5.05±0.75)d in the control group.The difference was statistically significant(P<0.05).After treatment,the study group had FVC of(2.30±0.24)L and PEF of(192.60±17.08)L/min,which were higher than(1.85±0.23)L and(169.55±18.20)L/min in the control group;the study group had lower CPIS score of(1.45±0.55)points than(1.87±0.42)points in the control group;the difference was statistically significant(P<0.05).After treatment,the levels of IL-6,TNF-αand CRP in the study group were(30.12±5.88)pg/ml,(30.45±4.85)pg/ml and(10.75±3.82)mg/L,which were lower than(35.24±7.08)pg/ml,(40.56±5.02)pg/ml and(14.28±3.70)mg/L in the control group.The difference was statistically significant(P<0.05).After treatment,the quality of life score of(88.85±5.45)points in the study group was higher than(82.65±6.02)points in the control group,and the difference was statistically significant(P<0.05).There was no difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The combination of Lianhua Qingwen Granules and azithromycin sequential therapy is effective in treating MP pneumonia in children.It can promote the recovery of symptoms and signs,improve lung function,pulmonary infection,and inflammatory factor levels,ensure quality of life,and has ideal safety,which is suitable for clinical promotion.